The gap can be tested by treating TLR4 priming as an upstream driver rather than a passive correlate. If true, perturbing butyrate-restoring consortia should shift fecal butyrate before downstream neurodegeneration markers change.
Curated pathway from expert analysis
flowchart TD
A["Gut Dysbiosis<br/>SCFA-Producing Bacteria Loss"]
B["Intestinal Permeability<br/>Leaky Gut Endotoxemia"]
C["LPS Translocation<br/>Portal and Systemic Circulation"]
D["TLR4 Activation<br/>MD-2 Coreceptor Complex"]
E["MyD88 Signaling<br/>NF-kappaB and MAPK Cascade"]
F["Peripheral Cytokine Storm<br/>IL-1beta and TNF Secretion"]
G["Microglial Priming<br/>Brain Resident Immune Activation"]
H["Neurodegeneration<br/>Synapse Loss and Tau Pathology"]
A --> B
B --> C
C --> D
D --> E
E --> F
F --> G
G --> H
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style D fill:#7b1fa2,stroke:#ce93d8,color:#ce93d8
style G fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style H fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9aMedian TPM across 13 brain regions for TLR4 priming from GTEx v10.
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for TLR4 priming.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No resource usage or linked notebooks recorded for this hypothesis yet.
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF TLR4 priming is the gut-dysbiosis driver of neuroinflammation, THEN fecal microbiota transfer from dysbiotic donors will raise microglial TLR4/NF-kB activation by >=30% within 6 weeks in germ-free | Recipient mice show >=30% increase in microglial TLR4/NF-kB activation markers versus healthy-donor FMT recipients. | — no observation — | pending | 0.65 |
| IF TLR4 is actionable upstream, THEN pharmacologic or genetic TLR4 inhibition will prevent at least 50% of dysbiosis-induced IL-1B/TNF microglial upregulation within 8 weeks. | TLR4 inhibition reduces dysbiosis-induced microglial IL-1B/TNF signal by >=50% versus untreated dysbiotic controls. | — no observation — | pending | 0.62 |